The application discloses application of
avobenzone in preparation of a preparation for reducing ATG14
protein content in cells; specifically, the
avobenzone can directly combine with the ATG14
protein, and promote the ATG14 to degrade the ATG14 through a
ubiquitin-
proteasome pathway (such as CUL3 mediation), so as to destroy the PI3KC3-C1 complex stability, inhibit the
autophagosome formation and reduce the
autophagy flux. Further, the
avobenzone can show a decrease in LC3-II lipidation level, a blocked p62 degradation and a damaged Beclin1-VPS34 complex
assembly. The application discloses, for the first time, a new application of the avobenzone as an
autophagy inhibitor targeting the ATG14, and provides a new technical scheme for ATG14-related
autophagy mechanism research and
drug screening.